Implementation of an amiodarone ambulatory care clinic

American Journal of Health-System Pharmacy

Volumn 66, Issue 22, 2009, Pages

  Tafreshi, Javad ^a   Chui, Michelle A ^b   Riley, Amy B ^c  

^a LOMA LINDA UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMBULATORY MONITORING; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; BLURRED VISION; CARDIAC PATIENT; CLINICAL EXAMINATION; CONSTIPATION; CORNEA DISEASE; COUGHING; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG WITHDRAWAL; DYSPNEA; ERECTILE DYSFUNCTION; FATIGUE; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HEART PALPITATION; HEART PROARRHYTHMIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFORMATION RETRIEVAL; LABORATORY TEST; LUNG INFILTRATE; LUNG TOXICITY; MEMORY DISORDER; NAUSEA; NEUROLOGIC DISEASE; OPTIC NEURITIS; OUTPATIENT DEPARTMENT; PARESTHESIA; PATIENT COMPLIANCE; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PHARMACIST; PHOTOSENSITIVITY; POLYNEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; SHORT SURVEY; SIDE EFFECT; SKIN DISCOLORATION; SKIN MANIFESTATION; SLEEP DISORDER; SYNCOPE; THYROID DISEASE; TREMOR; VISUAL DISORDER; WEAKNESS;

EID: 70450265585     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080555     Document Type: Short Survey

References (11)

1. McEvoy GK, Snow EK, Kester L et al., eds. Amiodarone. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists; 2006:1616-29.
2. Zipes DP, Camm AJ, Borggrefe M et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006; 48:e247-346.
3. Singh BN. Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Clin Cardiol. 1997; 20:608-618 (Pubitemid 27280497)
4. Bickford CL, Spencer AP. Adherence to the NASPE guideline for amiodarone monitoring at a medical university. J Manag Care Pharm. 2006; 12:254-259
5. Goldschlager N, Epstein AE, Naccarelli G et al. Practical guidelines for clinicians who treat patients with amiodarone. Arch Intern Med. 2000; 160:1741-1748 (Pubitemid 30418810)
6. Hilleman D, Miller MA, Parker R et al. Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy. 1998; 18(6, pt. 2):138S-145S. (Pubitemid 28533866)
7. Sanoski CA, Schoen MD, Conzalez RC et al. Rationale, development, and clinical outcomes of a multidisciplinary amiodarone clinic. Pharmacotherapy. 1998; 18(6, pt. 2):146S-151S.
8. Burgess C, Blaikie A, Ingham T et al. Monitoring the use of amiodarone: compliance with guidelines. Intern Med J. 2006; 36:289-293
9. Raebel MA, Carroll NM, Simon SR et al. Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. J Manag Care Pharm. 2006; 12:656-664
10. Stelfox HT, Ahmed SB, Fiskio J et al. Pharmacoepidemiology and drug utilization: monitoring amiodarone's toxicities: recommendations, evidence, and clinical practice. Clin Pharmacol Ther. 2004; 75:110-122
11. MedWatch. 2005 safety alert: Cordarone (amiodarone HCl). www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm150978.htm (accessed 2009 Aug 14).